Author: Ravi Shankar

ALLIS MED to lead regulatory certification process and serve as exclusive distributor for Baird Medical Microwave Ablation (MWA) products in key market

NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) — Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (“Baird Medical” or the “Company”), announced that it has entered into a strategic distribution partnership with ALLIS MED, a medical device distributor focused on the sale of surgical products and technologies to university hospitals and community medical centers.

Under the agreement, ALLIS MED will serve as Baird Medical’s Korea License Holder, and will manage regulatory submissions and interaction with the Ministry of Food and Drug Safety. Following receipt of product certification, ALLIS MED will become the exclusive distributor of Baird Medical’s products in South Korea.

Similar to other markets in Asia, thyroid tumor ablation procedures in South Korea are primarily performed using radiofrequency ablation. Through this partnership, which is designed to bring microwave ablation (“MWA”) technology to the country, Baird Medical and ALLIS MED aim to offer physicians another tool to address the needs of patients.

“Our entry into the South Korea market represents another important milestone in our ongoing global expansion strategy, while further strengthening our footprint in Asia,” said Haimei Wu, Chairwoman and CEO of Baird Medical. “Thus far in 2026, we have made inroads into multiple new markets, including Argentina, Egypt, Pakistan and Vietnam, while taking steps to strengthen our leadership position in the PRC and significantly expanding our commercial presence in the United States. These initiatives have helped to diversify our revenue base and create a stronger, more stable, global foundation for long-term growth. These achievements, coupled with recent technological and regulatory advancements including the FDA 510(k) and CE submissions for our Irreversible Electroporation System, position us well to continue our global market expansion efforts as we prepare to enter 2027.”

About Baird Medical

Baird Medical is a global, pioneering medical device company specializing in minimally invasive ablation technologies for a range of solid tumors. The Company’s lead product, a microwave ablation (MWA) system, is FDA-cleared for soft tissue ablation and is being launched in the U.S. primarily for the treatment of benign thyroid nodules. In addition, the Company is expanding its minimally invasive technology portfolio, including IRE-based products and an AI-powered robotic ablation system.

Baird Medical’s MWA solutions have been adopted by a growing number of leading U.S. institutions and private practice groups, including the Mayo Clinic, Columbia University Medical Center, and The George Washington University Hospital. The company is rapidly expanding its global commercial footprint, with sales now reaching markets across multiple continents.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical’s future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “could”, “should”, “expect”, “intend”, “might”, “will”, “estimate”, “anticipate”, “believe”, “budget”, “forecast”, “intend”, “plan”, “potential”, “predict”, or “continue”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Company’s Annual Report on Form 20-F, including those listed under the sections titled “Risk Factors” therein, and in Baird Medical’s other filings with the SEC.

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in Baird Medical’s most recent filings with the SEC. All subsequent written and oral forward-looking statements concerning Baird Medical, or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:

Lee Roth
Burns McClellan for Baird Medical
Lroth@burnsmc.com

– VIRAGE2 enrollment expected to complete in Q4 2026; initial data expected by Q3 2027 –

– Company completes sale of SYN-004 (ribaxamase) and related portfolio of antibiotic-degrading enzymes to Biossil Labs Inc. in October, 2026 for $350,000 upfront and up to $91 million in aggregate milestones as well as royalties –

– Detailed analyses of data from the VIRAGE Phase 2b clinical trial published in Nature Medicine –

– Cash and cash equivalents of $8.5 million as of September 30, 2026; cash runway into Q1 2027 –

ROCKVILLE, Md., Nov. 12, 2026 (GLOBE NEWSWIRE) — Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“We are pleased with the clinical progress achieved this quarter,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics. “Patient enrollment and dosing in the VIRAGE2 trial is progressing well, and we anticipate completing enrollment by the end of the fourth quarter of this year. The VIRAGE2 trial is a crucial step in the clinical advancement of VCN-01 as we evaluate a dosing regimen that is intended to maximize its potential clinical benefit in different cancer therapy combinations. The publication of detailed analyses of the results from the VIRAGE study in Nature Medicine was a gratifying validation of VCN-01’s novel mode of action and therapeutic potential in metastatic pancreatic ductal adenocarcinoma (PDAC). The recently signed asset sale agreement for SYN-004 (ribaxamase) and the related portfolio of antibiotic-degrading enzymes to Biossil Labs Inc. demonstrates our commitment to deriving value from our legacy microbiome programs while continuing to focus on the development of our lead program VCN-01. In parallel, we continue to evaluate strategic alternatives intended to maximize value for our stockholders.”

Recent Highlights and Anticipated Milestones

VCN-01

Metastatic PDAC:

• Two thirds of the target number of patients (4) have been dosed and enrollment is ongoing in the VIRAGE2 Phase 2a clinical trial evaluating the feasibility of more frequent repeated dosing of VCN-01 in combination with standard-of-care chemotherapy in first-line metastatic PDAC patients (EUCT: 2026-525566-21-00; NCT07701486). 

• • The VIRAGE2 trial builds on feedback from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) recognizing improved survival outcomes in the VIRAGE2 trial in metastatic PDAC patients receiving 2 doses of VCN-01 administered 3-months apart.
  • The VIRAGE2 trial is designed to evaluate the safety and feasibility of administering at least 3 doses of VCN-01 given approximately 2 months apart in combination with standard-of-care chemotherapy. The trial is expected to enroll 6 evaluable patients.
  • VIRAGE2 is expected to complete enrollment in Q4 2026, with initial pharmacodynamic and safety/tolerability data anticipated by Q3 2027.
  • Results from the VIRAGE2 study, if successful, are expected to inform the VCN-01 dosing regimen for future clinical trials evaluating VCN-01 in different cancer therapy combinations, including a potential pivotal Phase 3 clinical trial in metastatic PDAC.
• The detailed analyses of results from the VIRAGE Phase 2b trial evaluating VCN-01 in combination with gemcitabine/nab-paclitaxel standard-of-care chemotherapy in metastatic PDAC were recently published in Nature Medicine. The article is entitled “Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomised phase 2b trial” and can be read here.
  • The published analyses of data from the VIRAGE trial highlighted that repeated dosing of VCN-01 in combination with gemcitabine/nab-paclitaxel chemotherapy was well-tolerated, with improved overall survival, progression-free survival and duration of response compared with chemotherapy alone.
  • Improved survival outcomes were observed in patients treated with two doses of VCN-01 (given 3 months apart) without increased toxicity, providing the rationale for evaluating more frequent administration of additional VCN-01 doses in the VIRAGE2 trial.
  • Data from the published analyses are consistent with the immune-mediated mechanism of action for VCN-01 that may enhance the anti-tumor effects of a range of coadministered pancreatic cancer therapies.

Retinoblastoma:

• Discussions with key opinion leaders and the FDA are on-going regarding the design of a proposed Phase 2/3 clinical trial of intravitreal VCN-01 in combination with intravitreal topotecan in children with retinoblastoma with vitreous seeds that are refractory/resistant to the use of current intravitreal chemotherapy.
  • The proposed protocol builds on compelling Phase 1 clinical data in this ultra rare pediatric population for which there is no current treatment.
  • A Type C meeting completed with the FDA on August 31, 2026, provided guidance on the FDA’s current expectations for a clinical trial in this patient population, including proposed endpoints and statistical considerations. The FDA encouraged further discussion of the trial design with them, and additional interactions with the FDA are anticipated in Q1 2027.
  • VCN-01 has Orphan Drug Designation from the FDA, Orphan Medicinal Product Designation from the EMA and Rare Pediatric Disease Designation from the FDA for the treatment of retinoblastoma; if a Biologics License Application (BLA) for VCN-01 for the treatment of retinoblastoma is approved by the FDA by September 30, 2029, the Company may be eligible to receive a Priority Review Voucher.

SYN-004

• Theriva completed the sale of Theriva’s portfolio of antibiotic-degrading enzymes, including SYN-004 (ribaxamase), SYN-007 (reformulated ribaxamase), and SYN-006 (carbapenemase), pursuant to an asset sale agreement with Biossil Labs Inc. (“Biossil”).
  • Biossil acquired all rights, title and interest in SYN-004, SYN-007 and SYN-006, and assumed all responsibility and costs for development and commercialization of the assets.
  • Under the terms of the agreement, the Company received a $350,000 upfront payment upon closing and is eligible for an aggregate of up to $3 million in regulatory milestones and up to $88 million in sales milestones, as well as single-digit royalties on net product sales (capped at $250 million).
  • Concurrent with the Biossil asset sale, Theriva amended its Asset Purchase Agreement with PREV ABR LLC (from 2012) under which the Company originally acquired SYN-004 (ribaxamase) and the related product portfolio. Per the terms of the amendment, Theriva paid PREV ABR $140,000 upon receipt of the $350,000, and will be required to pay PREV 50% of future regulatory and sales milestone payments, 33⅓% of royalty payments received by Theriva, and 50% of other consideration received by Theriva in relation to the transferred assets, up to an aggregated total of $13 million.

Third Quarter Ended September 30, 2026 Financial Results

General and Administrative Expenses

General and administrative expenses decreased to $923,000 for the three months ended September 30, 2026, from $1.9 million for the three months ended September 30, 2025. This decrease of 51% primarily reflects a $841,000 decrease in the fair value of contingent consideration recognized in the three months ended September 30, 2026, compared to a $633,000 increase recognized in the same period in 2025, partially offset by a current year increase in legal fees. The charge related to stock-based compensation expense was $119,000 for the three months ended September 30, 2026, compared to $118,000 for the three months ended September 30, 2025.

Research and Development Expenses

Research and development expenses decreased to $612,000 for the three months ended September 30, 2026, from approximately $2.6 million for the three months ended September 30, 2025. This decrease of 76% is primarily the result of lower direct expenses related to the completion of the VCN-01 Phase 2b PDAC clinical trial, lower direct expenses related to VCN-01 manufacturing activities, lower direct clinical trial expenses related to the paused Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic HCT recipients, lower expenses related to SYN-020, partially offset by expenses associated with the conduct of the VIRAGE2 Phase 2a study in metastatic PDAC patients evaluating more frequent VCN-01 dosing for a longer period.

Other Income/Expense

Other income was $64,000 for the three months ended September 30, 2026, compared to other income of $79,000 for the three months ended September 30, 2025. Other income for the three months ended September 30, 2026 is comprised of interest income of $64,000. Other income for the three months ended September 30, 2025 is primarily comprised of interest income of $65,000 and an exchange gain of $14,000.

Cash and Cash Equivalents

Cash and cash equivalents totaled $8.5 million as of September 30, 2026, a decrease of $4.6 million from December 31, 2025. During the year ended December 31, 2025, and nine months ended September 30, 2026, the primary use of cash was for working capital requirements and operating activities, which resulted in a net loss of $23.7 million and $6.7 million for the year ended December 31, 2025, and the nine months ended September 30, 2026, respectively.

About Theriva™ Biologics, Inc.

Theriva™ Biologics (NYSE American: TOVX) is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s subsidiary Theriva Biologics, S.L., has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and intratumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead clinical-stage candidate is VCN-01 (zabilugene almadenorepvec), an oncolytic adenovirus designed to replicate selectively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. For more information, please visit Theriva™ Biologics’ website at www.therivabio.com.

Forward-Looking Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, and include statements regarding VIRAGE2 completing enrollment in Q4 2026, with initial pharmacodynamic and safety/tolerability data anticipated by Q3 2027; the VIRAGE2 trial being expected to enroll 6 evaluable patients; the results from the VIRAGE2 trial informing the VCN-01 dosing regimen for future clinical trials evaluating VCN-01 in different cancer therapy combinations, including a potential pivotal Phase 3 clinical trial in metastatic PDAC; the proposed Phase 2/3 clinical trial of intravitreal VCN-01 in combination with intravitreal topotecan in children with retinoblastoma with vitreous seeds that are refractory/resistant to the use of current intravitreal chemotherapy; continuing to evaluate strategic alternatives intended to maximize value for our stockholders; the potential payment from Biossil of up to $91 million in aggregate milestones as well as royalties on net product sales (capped at $250 million); the Company having a cash runway into Q1 2027; publication of detailed analyses of the results from the VIRAGE study in Nature Medicine providing a validation of VCN-01’s novel mode of action and therapeutic potential in metastatic pancreatic ductal adenocarcinoma (PDAC); the Company being eligible to receive a Priority Review Voucher if a Biologics License Application (BLA) for VCN-01 for the treatment of retinoblastoma is approved by the FDA by September 30, 2029, and additional discussions of the retinoblastoma clinical development plan with the FDA anticipated in Q1 2027. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to finalize protocols for future clinical trials evaluating VCN-01; results of future trials supporting further clinical development of VCN-01 and supporting the benefits of more frequent repeated dosing of VCN-01; the Company’s ability to obtain development funding and/or partnerships; the Company’s ability to receive any milestone or royalty payments from Biossil, the Company’s commencement of planned clinical trials, which remains subject to sufficient financing; the Company’s ability to raise capital and/or enter into one or more strategic alternatives, that may include a business combination, merger or reverse merger; the Company’s ability to reach clinical milestones when anticipated, including the ability to continue to enroll patients as planned; generating clinical data that establishes VCN-01 may improve patient outcomes in cancer patients; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, including approval of VCN-01 to treat cancer patients; regulatory limitations relating to the Company’s ability to promote or commercialize its product candidates for the specific indications; acceptance of the Company’s product candidates in the marketplace; the successful development, marketing or sale of the Company’s products; developments by competitors that render such products obsolete or non-competitive; the Company’s ability to maintain license agreements; the continued maintenance and growth of the Company’s patent estate; the ability to continue to remain well financed; and other factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release is provided only as of the date of this release, and Theriva Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

For further information, please contact:

Investor Relations

Kevin Gardner

LifeSci Advisors, LLC 

kgardner@lifesciadvisors.com

Theriva Biologics, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (In thousands except share and par value amounts)
		September 30, 2026				December 31, 2025
			(Unaudited)
Assets
Current Assets
Cash and cash equivalents		$	8,473			$	13,056
Tax credit receivable			1,673				3,351
Prepaid expenses and other current assets			475				1,060
Total Current Assets			10,621				17,467
Non-Current Assets
Property and equipment, net			155				222
Restricted cash			44				46
Right of use asset			1,704				803
In-process research and development			18,956				19,619
Deposits and other assets			80				82
Total Assets		$	31,560			$	38,239
Liabilities and Stockholders’ Equity
Current Liabilities:
Accounts payable		$	467			$	1,014
Accrued expenses			6,459				6,276
Accrued employee benefits			284				443
Deferred research and development tax credit-current portion			995				1,675
Loans payable-current			34				57
Operating lease liability-current portion			540				549
Total Current Liabilities			8,779				10,014
Non-current Liabilities
Non-current contingent consideration			8,978				10,004
Loan Payable – non-current			1,627				1,671
Non-current deferred research and development tax credit			197				815
Non-current operating lease liability			1,226				352
Total Liabilities			20,807				22,856
Commitments and Contingencies (Note 14)			—				—
Stockholders’ Equity:
Common stock, $0.001 par value; 350,000,000 shares authorized, 45,921,478 issued and 45,892,668 outstanding at September 30, 2026 and 35,717,159 issued and 35,688,350 outstanding at December 31, 2025			45				34
Additional paid-in capital			376,298				373,592
Treasury stock at cost, 28,810 shares at September 30, 2026 and at December 31, 2025			(288	)			(288	)
Accumulated other comprehensive income			140				755
Accumulated deficit			(365,442	)			(358,710	)
Total Stockholders’ Equity			10,753				15,383
Total Liabilities and Stockholders’ Equity		$	31,560			$	38,239

Theriva Biologics, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited)
		For the three months ended September 30,								For the nine months ended September 30,
		2026				2025				2026				2025
License Revenue		$	—			$	—			$	300			$	—
Operating Costs and Expenses:
General and administrative			923				1,889				5,025				14,516
Research and development			612				2,551				2,234				7,472
Total Operating Costs and Expenses			1,535				4,440				7,259				21,988
Loss from Operations			(1,535	)			(4,440	)			(6,959	)			(21,988	)
Other Income/Expense:
Foreign currency exchange gain			—				14				1				30
Interest income			64				65				226				215
Total Other Income			64				79				227				245
Net Loss before income taxes			(1,471	)			(4,361	)			(6,732	)			(21,743	)
Income tax benefit			—				—				—				—
Net Loss Attributable to Common Stockholders		$	(1,471	)		$	(4,361	)		$	(6,732	)		$	(21,743	)
Net Loss Per Share – Basic and Dilutive		$	(0.03	)		$	(0.45	)		$	(0.15	)		$	(3.38	)
Weighted average number of shares outstanding during the period – Basic and Dilutive			45,892,668				9,676,521				44,303,676				6,429,227
Net Loss			(1,471	)			(4,361	)			(6,732	)			(21,743	)
(Loss) gain on foreign currency translation			(107	)			(30	)			(615	)			1,941
Total comprehensive loss		$	(1,578	)		$	(4,391	)		$	(7,347	)		$	(19,802	)

Randomized, open-label, hypothesis-generating study (541 participants enrolled; 250 met final analysis criteria) evaluated two proprietary non-invasive neuromodulation technologies, electroCore’s cervical vagus nerve stimulation and Sonocea Sonic Augmentation Technology™ (SAT)

ROCKAWAY, N.J., Nov. 12, 2026 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced that results from a randomized, open label-controlled study evaluating non-invasive autonomic neuromodulation in adults with Long COVID have been published online in Neuromodulation: Technology at the Neural Interface.

The study, “Non-invasive Autonomic Regulatory Interventions for Long COVID: A Randomized Controlled Trial,” evaluated two non-invasive approaches designed to influence autonomic regulation: transcutaneous cervical vagus nerve stimulation (tcVNS) using proprietary electroCore technology and Sonocea Sonic Augmentation Technology™, a proprietary acoustic neuromodulation technology. The study evaluated each intervention independently as well as the combination of the two approaches.

Long COVID Represents a Major Unmet Medical Need

Long COVID has emerged as one of the most consequential chronic health challenges resulting from the COVID-19 pandemic. A 2024 review published in Nature Medicine¹ estimated that approximately 400 million people worldwide have experienced Long COVID, highlighting the extraordinary scale of this persistent global health problem.

The condition can persist for months or years and may involve multiple organ systems, with patients reporting fatigue, cognitive dysfunction or “brain fog,” sleep disturbance, shortness of breath, pain, cardiovascular symptoms, anxiety, post-traumatic stress symptoms, and autonomic dysfunction. In the United States, millions of adults continue to report Long COVID, and a substantial proportion of affected individuals report limitations in their daily activities.

The burden extends well beyond individual patients. Long COVID has been associated with impaired ability to work, increased healthcare utilization, reduced quality of life, and substantial economic losses. The same Nature Medicine review estimated the annual global economic impact as approaching approximately $1 trillion, while a separate U.S. economic analysis estimated the total societal cost of Long COVID in the United States at approximately $3.7 trillion,² reflecting reduced quality of life, lost earnings, and increased medical spending.

Despite the enormous number of people affected and extensive research efforts, treatment options remain limited. There is currently no FDA-approved therapy specifically for Long COVID as a condition, and clinical management remains largely directed toward individual symptoms and associated conditions. This substantial unmet need underscores the importance of investigating new therapeutic approaches capable of addressing the complex, multisystem nature of Long COVID.

Randomized Study of Autonomic Neuromodulation

The four-arm randomized study enrolled 541 participants, 250 of whom met the final analytic criteria (complete outcome data and, for active-intervention participants, at least 50% adherence). It compared electroCore’s cervical non-invasive vagus nerve stimulation (tcVNS), SAT, combined tcVNS plus SAT, and a monitoring-only control over four weeks. SAT was delivered through headphones using a smartphone-based protocol for 15 minutes twice daily; tcVNS consisted of two 2-minute stimulations twice daily.

Across the study, the active intervention groups demonstrated improvements across multiple Long COVID symptom domains compared with monitoring alone. Improvements were observed in measures encompassing fatigue, breathing, cognition, sleep, mental health, circulation and the impact of symptoms on daily life.

Depressive symptom scores decreased by approximately 33% with electroCore’s cervical non-invasive vagus nerve stimulation, 31% with Sonocea’s Sonic Augmentation Technology, and 34% with the combination, compared with approximately 2% in the monitoring-only control group; each active intervention demonstrated a statistically significant within-group improvement (p < 0.001) and the change over time differed significantly across the four study groups. The combined intervention was associated with an approximately 39% reduction in PTSD-related symptom scores, compared with an increase of approximately 6% in the monitoring-only group. However, direct comparisons among the three active intervention groups did not show statistically significant differences, including on PTSD-related symptoms, and the study does not establish superiority of the combined intervention.

Improvements were also observed in fatigue, cognitive symptoms, breathing, and other measures of Long COVID symptom burden.

These results come from an open-label study without a sham control and are considered hypothesis-generating; key limitations are described below.

“Long COVID represents an enormous unmet medical need,” said Peter S. Staats, M.D., MBA, Chief Medical Officer and Co-Founder of electroCore and lead author of the study. “Millions of people continue to experience symptoms that can affect multiple aspects of their health and their ability to work and function, yet we still have no FDA-approved therapy specifically for Long COVID as a condition. That makes the search for new therapeutic approaches particularly important.

What makes these findings especially interesting is that we evaluated two distinct, non-pharmacologic approaches to autonomic neuromodulation—direct cervical non-invasive vagus nerve stimulation and a novel acoustic intervention—and observed improvements across multiple symptom domains. Long COVID is unlikely to have a single cause or a single solution, but these results suggest that autonomic regulation may represent a potential therapeutic target worthy of further investigation in larger, sham-controlled studies.”

The study was conducted remotely in adults with symptoms persisting at least three months following COVID-19 infection. Participants were randomized to monitoring alone, SAT, cervical tcVNS, or combined SAT and tcVNS. The primary endpoint was change in domains from the Symptom Burden Questionnaire for Long COVID (SBQ-LC), with additional validated, self-reported measures assessing anxiety, depression, post-traumatic stress symptoms, autonomic symptoms, and self-reported biobehavioral state.

The investigators noted several limitations, including the open-label design, absence of a sham-stimulation control, reliance primarily on patient-reported outcomes, the absence of objective physiological measures of autonomic function, the facts that participants’ treatment expectations were not assessed, participant attrition, and the absence of correction for multiple comparisons. Accordingly, the findings are considered hypothesis-generating and warrant confirmation in future sham-controlled studies incorporating objective physiological measures and longer follow-up.

The study was funded by the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense, which had no role in data analysis, interpretation, manuscript preparation or the decision to publish the study results. The views expressed in this release are those of the authors and the Company and do not necessarily reflect the official policy or position of the Department of Defense or the U.S. Government, and no endorsement should be inferred. Participant monitoring, randomization, data collection and database management were conducted by Leidos, an independent third party. Dr. Staats is a co-founder and Chief Medical Officer of electroCore, and co-author Stephen W. Porges, Ph.D., is a founder of Sonocea.

A Potential New Therapeutic Direction

Long COVID is increasingly understood as a heterogeneous, multisystem condition that may involve interacting immune, inflammatory, vascular, metabolic, neurological and autonomic mechanisms. This complexity may help explain why finding a single effective pharmacologic treatment has proven difficult.

The authors hypothesized that interventions capable of influencing autonomic regulation through different pathways could provide another approach to addressing the broad symptom burden experienced by some patients. Cervical non-invasive vagus nerve stimulation is intended to engage the vagus nerve in the neck, while SAT uses patterned auditory stimulation intended to influence central neural networks involved in autonomic regulation.

The observation that both approaches were associated with improvements provides support for further investigation of autonomic neuromodulation as an investigational, non-pharmacologic therapeutic strategy for Long COVID.

Neither electroCore’s cervical non-invasive vagus nerve stimulation nor Sonocea Sonic Augmentation Technology (SAT) has been cleared or approved by the FDA for the treatment of Long COVID. The safety and effectiveness of the technologies for Long COVID have not been established.

About electroCore, Inc.
electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance. Truvaga™ and TAC-STIM™ are not intended to diagnose, treat, cure, mitigate or prevent any disease or condition, including Long COVID.

For more information, visit www.electrocore.com.

About Sonocea Inc.
Sonocea Inc. is a neuroscience technology company developing non-invasive acoustic neuromodulation approaches to support autonomic nervous system regulation. Its proprietary Sonic Augmentation Technology™ (SAT) uses a novel signal-generation architecture to create structured acoustic interventions delivered through ordinary headphones or speakers.

References
Cutler DM. The Costs of Long COVID. JAMA Health Forum. 2022;3(5):e221809. doi:10.1001/jamahealthforum.2022.1809

Al-Aly Z, Davis H, McCorkell L, et al. Long COVID science, research and policy. Nature Medicine. 2024;30:2148–2164. doi:10.1038/s41591-024-03173-6

Staats PS, Dana AN, Lawrence T, Porges SW. Non-invasive autonomic regulatory interventions for Long COVID: a randomized controlled trial. Neuromodulation: Technology at the Neural Interface. 2026. doi: 10.1016/j.neurom.2026.09.025.

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding the potential implications of the study described in the release and of future research involving non-invasive vagus nerve stimulation or acoustic neuromodulation for Long COVID; the possible design, conduct or results of any future studies; the possible development, regulatory review or commercialization of technologies or products for Long COVID and other indications; the Company’s future business strategies, growth opportunities, prospects, product development and market expansion; and other statements that are not historical in nature, particularly those using terms such as “anticipates,” “will,” “expects,” “believes,” “intends,” “may,” “potential” and similar expressions.

Actual results could differ materially from those projected in any forward-looking statement because of numerous factors, including the preliminary, hypothesis-generating nature of the findings described in this release; the open-label design of the study, the absence of a sham-stimulation control, the absence of objective physiological measures, reliance primarily on patient-reported outcomes, participant attrition and the absence of correction for multiple comparisons; the risk that future studies may not confirm these findings; the need for additional analysis and replication; uncertainties inherent in developing new products, technologies, or indications; the Company’s ability to obtain any required regulatory clearances or approvals for new products, including for Long COVID; the Company’s dependence on third parties, including Sonocea, for technologies evaluated in the study; the ability to commercialize products; the performance, adoption and market acceptance of non-invasive vagus nerve stimulation products; electroCore’s results of operations and financial performance; inflation and currency fluctuations; competition in the industry; and overall economic and market conditions.

Forward-looking statements speak only as of the date of this press release. electroCore assumes no obligation to update any forward-looking statement or the reasons actual results could differ from those projected, except as required by law. Investors should review the information in this release together with the risk-factor disclosures in electroCore’s reports and other documents filed with the U.S. Securities and Exchange Commission at www.sec.gov.

Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com

---

¹ Al-Aly Z, Davis H, McCorkell L, et al. Long COVID science, research and policy. Nature Medicine. 2024;30:2148–2164. doi:10.1038/s41591-024-03173-6.
² Cutler DM. The economic cost of Long COVID: An update. Harvard University. 2022. https://scholar.harvard.edu/files/cutler/files/long_covid_update_7-22.pdf 

IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer

Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by the first quarter of 2029, supported by strong Phase 2 clinical data showing significant overall survival benefit

Conference call to be held today at 11:00 a.m. EST

LAWRENCEVILLE, N.J., Nov. 12, 2026 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today reported financial results for the three months and nine months ended September 30, 2026, and highlighted recent business updates including progress in advancing Phase 3 clinical development of its lead candidate IMNN-001 in newly diagnosed advanced ovarian cancer.

“IMUNON continues to make significant progress in the clinical development of IMNN-001 for advanced ovarian cancer,” said Stacy R. Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. “The data generated to date, our collaboration with the National Cancer Institute, and the favorable safety profile observed across studies support the ongoing advancement of the program and its potential to provide a transformative treatment for women with this difficult disease. We believe the OVATION 3 study is well positioned, with a broad patient population, two planned interim analyses, and a development strategy designed to support efficient execution and evaluation of the treatment’s potential benefit.”

“We have also taken steps to continue to sharpen our strategic focus and strengthen IMUNON’s financial position. Through our agreement to transition ThermoDox^® to a dedicated development partner and our recent debt-for-equity exchange, we are demonstrating the disciplined approach to capital allocation that we believe is essential to advancing our most significant clinical opportunity while preserving opportunities for future value creation. As we look ahead, our priorities remain clear: execute OVATION 3, build on the growing body of evidence supporting IMNN-001 and advance a potentially transformative new treatment option for women who urgently need better outcomes.”

RECENT DEVELOPMENTS

IMNN-001:

On July 23, 2026, the Company announced that translational and clinical data on IMNN-001 were presented at the inaugural AACR Conference on Drug Discovery and Development (AACR D3), held July 21–24, 2026, in Boston. The presentation included findings from the randomized Phase 2 OVATION 2 study demonstrating that IMNN-001 was safe and well-tolerated, achieved local delivery of IL-12, and induced anti-tumoral immune responses, with no cytokine release syndrome or higher incidence of immune-related events observed in the experimental arm compared with control. Translational analyses indicated that IMNN-001 enhanced favorable ratios of CD8+ T cells to regulatory T cells and CD8+ to CD4+ cells in tumors and the tumor microenvironment, consistent with previously reported associations with improved outcomes. These findings support the ongoing pivotal Phase 3 OVATION 3 trial, which is designed to confirm the safety and survival benefit of IMNN-001 in frontline advanced ovarian cancer.

On September 10, 2026, the Company announced it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health. Under the CRADA, the NCI’s Cancer Therapy Evaluation Program (CTEP), which will assume regulatory sponsorship, will support further clinical and non-clinical development of IMNN-001 under the NCI Experimental Therapeutics (NExT) Program. IMNN-001 is the first gene-based immunotherapy selected by NCI/CTEP for partnered clinical development under a CRADA.

On September 22, 2026, the Company announced that the Independent Data Monitoring Committee (IDMC) overseeing its ongoing Phase 2 minimal residual disease (MRD) translational study of IMNN-001 recommended that the study continue without modification, identifying no new safety signals and confirming comparable safety across both treatment arms.

On September 23, 2026, the Company hosted its 2026 R&D Day in New York, featuring presentations from the lead clinical investigators on the completed Phase 2 OVATION 2 study, the pivotal Phase 3 OVATION 3 study and the Phase 2 MRD study, together with translational data on how IMNN-001 remodels the tumor immune microenvironment. A replay is available on the Scientific Presentations page of the Company’s website, accessible through this webcast link.

On November 6, 2026, the Company announced new translational data from its randomized Phase 2 OVATION 2 study of IMNN-001 in newly diagnosed advanced ovarian cancer. The data are being presented in a poster at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting (SITC 2026), being held November 4–8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.

Corporate Development:

On September 29, 2026, the Company entered into an Exchange Agreement, under which $1.2 million of outstanding debt, together with accrued and unpaid interest, was exchanged for shares of the Company’s newly designated, non-convertible Series B Preferred Stock. The transaction reduces the outstanding balance of the Company’s A-1 Note by approximately 43% and increases stockholders’ equity while preserving financial flexibility, with no issuance of common stock or warrants.

On October 21, 2026, the Company announced that it had entered into an agreement to sell its rights to ThermoDox^®, a heat-activated liposomal formulation of doxorubicin, to VoxelDox Therapeutics, Inc. (“VoxelDox”). Under the agreement, closing of which is contingent on VoxelDox raising $2.5 million in funding, VoxelDox intends to advance the development of ThermoDox for the treatment of glioblastoma multiforme. In exchange, IMUNON will receive an equity ownership stake in VoxelDox, payments of up to $16.5 million contingent upon meeting development milestones and significant royalties on future net sales of ThermoDox product following commercial approval.

On October 27, 2026, the Company filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed offering of its securities. The registration statement has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

FINANCIAL RESULTS FOR THE THIRD QUARTER 2026

Net loss available to common shareholders for the third quarter of 2026 was $3.8 million, or $0.64 per share, compared with a net loss of $3.4 million, or $1.16 per share, for the third quarter of 2025. Operating expenses were $3.4 million for the third quarter of 2026, largely unchanged from $3.5 million for the third quarter of 2025.

Research and development expenses were $1.8 million in the third quarter of 2026, compared with $1.9 million in the same period of 2025. Clinical costs associated with the OVATION studies were $0.4 million, compared with $0.5 million in the corresponding period in 2025. As enrollment in the OVATION 3 Study advanced, these costs were offset by lower manufacturing and clinical supply costs and lower other clinical and regulatory costs.

General and administrative expenses increased to $1.7 million in the third quarter of 2026, compared with $1.6 million in the same period of 2025, primarily reflecting higher outside professional fees.

FINANCIAL RESULTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026

Net loss available to common shareholders for the nine months ended September 30, 2026 was $10.9 million, or $2.01 per share, compared with a net loss of $10.3 million, or $5.53 per share, for the same period of 2025. Operating expenses were $10.5 million for the nine months ended September 30, 2026, compared with $10.4 million for the same period of 2025.

Research and development expenses increased to $5.6 million for the nine months ended September 30, 2026, compared with $5.3 million in the same period of 2025. Clinical costs associated with the OVATION studies of $0.8 million were flat with the comparable period in 2025, and manufacturing and clinical supply costs supporting the OVATION and MRD programs increased to $3.3 million from $3.0 million, partially offset by lower costs associated with the MRD Study and the closeout of the OVATION 2 Study.

General and administrative expenses were $5.0 million for the nine months ended September 30, 2026, largely unchanged from $5.1 million for the same period of 2025.

Net cash used in operating activities was $10.2 million for the nine months ended September 30, 2026, unchanged from the same period last year. At September 30, 2026, cash and cash equivalents were $4.0 million, and the Company held an additional $5.0 million of restricted cash.

Conference Call and Webcast

The Company will host a conference call to review third quarter 2026 financial results and provide a business update today, November 12, 2026, at 11:00 a.m. EST. To participate in the call, please dial (800) 715-9871 (U.S. and Canada/Toll Free) or (646) 307-1963 (U.S./Toll) and ask for the IMUNON Third Quarter 2026 Financial Results Call (Conference ID 4174261). A live webcast of the call will also be available here.

An audio replay of the call will be available for 90 days and can be accessed at (800) 770-2030 (U.S. and Canada/Toll Free) or (609) 800-9909 (U.S./Toll) using replay access code 4174261#.

About IMUNON

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The lead modality, TheraPlas^®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials, including one Phase 2 clinical trial (OVATION 2), and is currently being studied in a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. The Company will continue to leverage its modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.

Forward-Looking Statements

IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding expectations regarding the timing and enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact:
Valter Pinto
KCSA Strategic Communications
212-896-1254
imunon@kcsa.com

(Tables to Follow)

IMUNON, Inc.
Condensed Consolidated Statements of Operations
(in thousands except per share amounts)

		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Operating expenses: Research and development		$	1,793			$	1,899			$	5,595			$	5,291
General and administrative			1,655				1,577				4,951				5,098
Total operating expenses			3,448				3,476				10,546				10,389
Loss from operations			(3,448	)			(3,476	)			(10,546	)			(10,389	)
Other (expense) income			(302	)			47				(267	)			117
Net loss		$	(3,750	)		$	(3,429	)		$	(10,813	)		$	(10,272	)
Deemed dividend – preferred stock			(63	)			–				(82	)			–
Net loss available to common shareholders		$	(3,813	)		$	(3,429	)		$	(10,895	)		$	(10,272	)
Net loss per common share
Basic and diluted		$	(0.64	)		$	(1.16	)		$	(2.01	)		$	(5.53	)
Weighted average shares outstanding
Basic and diluted			5,947				2,944				5,408				1,856

IMUNON, Inc.
Selected Balance Sheet Information
(in thousands)

		September 30, 2026				December 31, 2025
ASSETS
Current assets
Cash and cash equivalents		$	4,039			$	8,781
Advances, deposits on clinical programs and other current assets			1,799				1,943
Total current assets			5,838				10,724
Property and equipment			394				530
Other assets
Restricted cash			5,039				–
Operating lease right-of-use assets			687				984
Deposits and other assets			51				50
Total other assets			5,777				1,034
Total assets		$	12,009			$	12,288
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable and accrued liabilities		$	2,414			$	4,217
Note payable – current portion Note A			1,380				–
Operating lease liability – current portion			445				407
Total current liabilities			4,239				4,624
Note Payable – Note B			4,884				–
Operating lease liability – noncurrent portion			263				602
Total liabilities			9,386				5,226
Stockholders’ equity
Preferred stock, including additional paid-in capital			3,384				–
Common stock			62				34
Additional paid-in capital			431,373				428,411
Accumulated deficit			(432,111	)			(421,298	)
			2,708				7,147
Less: Treasury stock			(86	)			(85	)
Total stockholders’ equity			2,622				7,062
Total liabilities and stockholders’ equity		$	12,009			$	12,288

# # #

OPHI marks another important step in CollPlant’s strategy to expand and focus its operations built around LightSolver’s all-optical Laser Processing Unit (LPU)™

Rehovot, Israel, Nov. 12, 2026 (GLOBE NEWSWIRE) — CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) (“CollPlant”) today announced that its ordinary shares will begin trading on Nasdaq under the new ticker symbol “OPHI,” effective at the open of trading on November 13, 2026. The shares will continue to trade under “CLGN” through the close of trading on November 12, 2026.

No action is required by shareholders in connection with the ticker symbol change. The ordinary shares will continue to be listed on Nasdaq and CollPlant’s CUSIP number will remain unchanged.

“Changing our ticker symbol to OPHI reflects our strategic expansion into photonic computing,” said Eran Rotem, Chief Executive Officer and CFO of CollPlant. “By building our future around LightSolver’s LPU technology, we believe we are positioned to address next-generation computing demands and deliver long-term value to our shareholders.”

“As the world’s demand for computing power keeps growing, the industry is looking for fundamentally new approaches,” said Dr. Ruti Ben Shlomi, Co-Founder and CEO of LightSolver. “Our LPU uses interacting lasers to perform the computation itself, with the potential to solve demanding workloads at significantly higher speeds while reducing energy consumption.”

Subject to shareholder approval at CollPlant’s extraordinary general meeting scheduled for November 24, 2026 and the consent of the Israeli Registrar of Companies, CollPlant intends to change its name to OptiPhi Computing Ltd. For additional details, please see CollPlant’s announcement dated November 4, 2026.

About CollPlant
CollPlant (Nasdaq: CLGN) is an innovative technology company operating at the intersection of deep-tech photonic computing and advanced biotechnology. Through its subsidiary LightSolver, CollPlant is advancing the development of proprietary all-optical laser-based computing architectures designed to resolve the world’s most demanding computational bottlenecks across artificial intelligence, aerospace, financial engineering, and high-performance computing. CollPlant also retains its proprietary plant-derived recombinant human collagen (rhCollagen) and bio-ink assets, for 3D bioprinting of tissues and organs and medical aesthetics. For more information about CollPlant, visit www.collplant.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the expected timing of trading of CollPlant’s ordinary shares under the new ticker symbol; the proposed change of CollPlant’s name; the anticipated performance, capabilities and energy efficiency of the LPU; the long-term value of CollPlant’s photonic computing business; and the future prospects, business plans and growth strategies of CollPlant and LightSolver. Forward-looking statements can be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “may,” “should,” “could,” “might,” “seek,” “target,” “will,” “project,” “continue,” “potential” and similar expressions or the negative of such terms. These forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the risk that shareholder approval of the proposed name change or the consent of the Israeli Registrar of Companies is not obtained, or that the name approved differs from the proposed name; LightSolver’s ability to scale its technology from prototype to a commercial product; risks associated with integrating LightSolver’s business, operations and personnel; LightSolver’s ability to achieve anticipated technological and commercial milestones; uncertainties regarding market acceptance and adoption of LightSolver’s technology; the ability to develop and commercialize LightSolver’s products and technology successfully; the ability to establish and expand strategic collaborations and commercial relationships; competition and technological developments; intellectual property risks; the availability of capital; CollPlant’s ability to maintain compliance with Nasdaq listing requirements; general market, industry, economic and geopolitical conditions; and other risks and uncertainties described in CollPlant’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F and subsequent Reports on Form 6-K. Forward-looking statements speak only as of the date of this press release. CollPlant undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investors Contact
CollPlant Biotechnologies
investors@lightsolver.com

Arx Investor Relations
North American Equities Desk
collplant@arxhq.com

MINNEAPOLIS, Nov. 12, 2026 (GLOBE NEWSWIRE) — Northern Technologies International Corporation (NASDAQ: NTIC) today announced that it expects to release its fiscal 2026 fourth-quarter financial results on Thursday, November 19, 2026, before the market opens. A copy of the news release will be available on the Investor Relations section of NTIC’s webpage (www.ntic.com).

In conjunction with NTIC’s release of its financial and operating results, investors, analysts, and other interested parties are invited to participate in a conference call with management on Thursday, November 19, 2026, at 9:00 a.m. Eastern Time.

Gautam Ramdas, President and CEO, and Matt Wolsfeld, CFO, will review NTIC’s fiscal 2026 fourth-quarter financial results and outlook, which will be followed by a question-and-answer session.

Details for the conference call are as follows.

CONFERENCE CALL CONFIRMATION:

NTIC Fiscal 2026 Fourth-Quarter Earnings Conference Call and Webcast

November 19, 2026, at 9:00 A.M. ET (8:00 A.M. CT, 7:00 A.M. MT, 6:00 A.M. PT)

Live Call Participants Registration URL:

https://register-conf.media-server.com/register/BI4b45910c813d4d2da91b95edfc3a9504

To join the live call and ask a question, a participant must register using the URL above. Once registered, the participant will receive a dial-in number and unique PIN number to access the call.

URL EVENTS & PRESENTATIONS WEBPAGE:

The audio-only webcast can be accessed at the following link: https://edge.media-server.com/mmc/p/xbx34br2. A link to the webcast is also available on the Investor Relations section of NTIC’s webpage. Participants are advised to go to the website at least 15 minutes early to register, download and install any necessary audio software. For those unable to participate in the live webcast, a replay of the webcast will be archived and accessible for approximately one year on the Investor Relations section of NTIC’s webpage.

About Northern Technologies International Corporation

Northern Technologies International Corporation develops and markets proprietary, environmentally beneficial products and services in over 65 countries either directly or via a network of subsidiaries, joint ventures, independent distributors and agents. NTIC’s primary business is corrosion prevention marketed mainly under the ZERUST® brand. NTIC has been selling its proprietary ZERUST® rust and corrosion inhibiting products and services to the automotive, electronics, electrical, mechanical, military and retail consumer markets for over 50 years and more recently has also targeted and expanded into the oil and gas industry. NTIC offers worldwide on-site technical consulting for rust and corrosion prevention issues. NTIC’s technical service consultants work directly with the end users of NTIC’s products to analyze their specific needs and develop systems to meet their technical requirements. NTIC also markets and sells a portfolio of bio-based and biodegradable polymer resin compounds and finished products marketed under the Natur-Tec® brand.

Investor and Media Contact:
Matthew Wolsfeld, CFO
(763) 225-6600

HOUSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) — Weatherford International plc (NASDAQ: WFRD) (“Weatherford” or the “Company”) today announced that it expects to complete its previously announced redomestication to Delaware on Friday, November 13, 2026.

As part of the redomestication, Weatherford International plc ordinary shares are expected to stop trading on Nasdaq after market close on Thursday, November 12, 2026. Weatherford International Corp common stock is expected to begin trading on Friday, November 13, 2026, under the new CUSIP number 94708K 103. Shareholders do not need to take any action as a result of this change, and the Company’s ticker symbol (WFRD) will not change.

About Weatherford

Weatherford is a global energy services company that helps customers drill smarter, complete wells more effectively, and maximize production across the entire well lifecycle. With a differentiated portfolio of market-leading solutions, integrated technologies, and a broad global customer footprint across six continents, we blend advanced engineering, digital intelligence, and world-class field expertise to reduce risk, improve performance, and maximize the value of customer assets. Together, we elevate every operation, delivering stronger wells, sharper decisions, and better energy for the world. Visit weatherford.com for more information and connect with us on social media.

Forward-Looking Statements

This release, as well as other statements we make, includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not historical facts, including statements about Weatherford’s beliefs, plans, estimates, or expectations, are forward-looking statements. Forward-looking statements often use words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “plan,” “potential,” “should,” “target,” “will,” and other words of similar meaning. Such forward-looking statements include, but are not limited to, statements regarding the Redomestication, the related restructuring activities and the expected timing and financial implications. These statements are based on current beliefs, plans, estimates, and expectations, all of which involve risk and uncertainty. Actual results may differ materially from those included in such forward-looking statements and therefore you should not place undue reliance on them.

The factors that could cause actual results to differ materially from current expectations include, but are not limited to, our ability to realize the expected benefits from the Redomestication; the occurrence of difficulties in connection with the Redomestication, including any costs related thereto; the risk that the Redomestication disrupts current plans and operations; any changes in tax laws, tax treaties or tax regulations or the interpretation or enforcement thereof by the tax authorities in Ireland, the United States and other jurisdictions following the Redomestication; and the future financial performance of Weatherford following the Redomestication.

The foregoing factors are in addition to those other risks, uncertainties, and factors included in the “Risk Factors” section and elsewhere in Weatherford’s reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and other documents filed with the SEC. There may be other risks and uncertainties that we are not currently aware of or are unable to predict and which may also affect Weatherford’s forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements and Weatherford undertakes no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

For Investors:
Luke Lemoine
Senior Vice President, Corporate Development & Investor Relations
+1 713-836-7777
investor.relations@weatherford.com

For Media:
Kelley Hughes
Vice President, Communications, Marketing & Sustainability
media@weatherford.com

WILMETTE, Ill., Nov. 12, 2026 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced third quarter 2026 financial results and provided business updates.

Recent Program Developments

ALXN1840 for Wilson Disease

On November 8, 2026, Monopar presented baseline findings from the Phase 3 FoCus study of ALXN1840 (tiomolibdate choline, TMC), the largest randomized controlled trial ever conducted in Wilson disease, characterizing residual disease burden in treatment-experienced patients at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2026. Baseline rates in treatment-experienced and treatment-naïve patients were 39% and 30% for cirrhosis, 79% and 83% for neurologic symptoms, and 75% and 70% for psychiatric symptoms, respectively. Among evaluable patients, 73% had at least two of these manifestations. Only 47% of treatment-experienced patients were within the guideline-recommended copper target range. Among patients receiving standard-of-care therapy for more than 12 months, 31% had 24-hour urinary copper excretion above that range.

On November 5, 2026, Monopar presented a poster at AASLD reporting neutral molybdenum balance and lack of molybdenum toxicity in subjects treated with ALXN1840, with serum uric acid remaining within normal limits over six years of treatment. These findings are consistent with ALXN1840’s known albumin tripartite complex (ATC) mechanism and provide further evidence supporting its long-term safety profile.

On August 19, 2026, Monopar announced the appointment of Jeffrey D. Kent, M.D., FACP, FACG, as Executive Vice President, Head of Medical Affairs. Dr. Kent is leading the Company’s medical affairs organization as Monopar prepares for potential U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA) for ALXN1840, its first-in-class ATC activator drug candidate for the treatment of Wilson disease. Dr. Kent brings more than 20 years of biopharmaceutical leadership experience across medical affairs, clinical development and regulatory strategy, with expertise spanning rare diseases, hepatology and gastroenterology, immunology and specialty therapeutics.

On July 22, 2026, Monopar announced it had initiated the rolling submission of an NDA to the FDA for ALXN1840. The FDA authorized Monopar to submit the NDA on a rolling basis, allowing completed sections of the application to be submitted and reviewed while the Company finalizes the remaining sections. The Company is on track to complete the NDA submission within the next several weeks.

Financial Results for the Third Quarter Ended September 30, 2026, Compared to the Third Quarter Ended September 30, 2025

Cash and Net Loss

Cash, cash equivalents and investments as of September 30, 2026, were $129.4 million. Monopar expects its current funds to support operations through at least March 31, 2028, including: (1) regulatory and potential commercial activities for ALXN1840; (2) continued development of MNPR-101 programs; and (3) internal research and development.

Net loss for the third quarter of 2026 was $6.2 million, or $0.72 per share, compared to net loss of $3.4 million, or $0.48 per share, for the third quarter of 2025.

Research and Development (“R&D”) Expenses

R&D expenses for the third quarter of 2026 were $4,436,543 compared to $2,589,749 for the third quarter of 2025. This represents an increase of $1,846,794 primarily attributed to (1) a $1,772,461 increase in R&D contractor and consulting expenses, (2) a $909,699 increase in R&D personnel expenses including stock-based compensation, (3) a decrease of $709,250 in manufacturing activities related to ALXN1840, and (4) a net decrease of $126,116 in other R&D expenses.

General and Administrative (“G&A”) Expenses

G&A expenses for the third quarter of 2026 were $3,031,302 compared to $1,503,326 for the third quarter of 2025. This represents an increase of $1,527,976 primarily attributed to (1) a $973,753 increase in G&A personnel expenses including stock-based compensation, (2) a $353,963 increase in G&A contractor and consulting expenses, and (3) a net increase of $200,260 in other G&A expenses.

Interest Income (Loss)

Interest income for the third quarter of 2026 was $1,271,370 compared to $655,473 for the third quarter of 2025. The increase is attributed to interest earned on U.S. Treasury securities and commercial paper and to higher bank balances in 2026 due to the net proceeds of approximately $91.9 million from the September 2025 capital raise.

About Wilson Disease

Wilson disease is a rare genetic disorder that affects approximately 1 in 30,000 people worldwide. It is caused by mutations in the ATP7B gene, which impairs the body’s ability to excrete copper. It is characterized by toxic accumulation of copper in the liver, brain, and other organs, leading to progressive and potentially fatal outcomes if untreated.

About ALXN1840

ALXN1840 (tiomolibdate choline, TMC) is a novel first-in-class albumin tripartite complex (ATC) activator under investigation for the treatment of Wilson disease. ALXN1840 rapidly mobilizes and tightly sequesters excess copper in stable ATCs, suppressing copper’s redox reactivity, limiting oxidative damage, and blocking its transport across the blood–brain barrier. Clinical data have also demonstrated that ALXN1840 improves copper balance by increasing fecal copper excretion.

In the pivotal Phase 3 trial, ALXN1840 met its primary endpoint, demonstrating rapid and sustained copper mobilization that was significantly greater than standard of care over 48 weeks in both previously treated and treatment-naïve patients. Across the ALXN1840 clinical development program, durable clinical improvement and favorable tolerability were observed across 645 patient-years of follow-up in 266 patients, with a well-characterized safety profile.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage ALXN1840 for Wilson disease, and radiopharmaceutical programs including MNPR-101-Zr (Phase 1) for imaging advanced cancers along with MNPR-101-Lu (Phase 1a) and MNPR-101-Ac (late preclinical) for the treatment of advanced cancers. For more information, and links to SEC filings that contain detailed financial information, visit: https://ir.monopartx.com/quarterly-reports.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning the following: that Dr. Kent is leading the Company’s medical affairs organization as Monopar prepares for potential U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA) for ALXN1840; that the Company is on track to complete the NDA submission within the next several weeks; and that Monopar expects its current funds to support operations through at least March 31, 2028. The forward-looking statements involve risks and uncertainties including, but not limited to, uncertainties related to the Company’s ability to complete the NDA submission within the anticipated timeframe; whether the FDA will accept the NDA for filing, require additional information or studies, or approve ALXN1840; the timing of FDA review; the risk that changes in operating plans, development or commercialization costs, or the timing and amount of contractual milestone payments could shorten the Company’s expected cash runway; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

CONTACT: 

Monopar Therapeutics Inc.
Investor Relations
Quan Vu
Chief Financial Officer
vu@monopartx.com

Follow Monopar on social media for updates:

X: @MonoparTx LinkedIn: Monopar Therapeutics

BLA submission for miv-cel in SPS completed with request for priority review 

Commercial readiness advancing for potential U.S. launch of miv-cel, which would become the first approved therapy for SPS and first approved CAR-T therapy in autoimmune disease

KYSA-6 Phase 3 gMG trial enrollment on-track for completion in mid-2027

Miv-cel’s clinical profile continues to set the benchmark for autoimmune CAR T, demonstrating durable clinical benefit and a consistent, well-tolerated safety profile across multiple neurologic autoimmune indications

EMERYVILLE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today reported portfolio progress and financial results for the third quarter ended September 30, 2026.

“Kyverna is very proud to submit the first BLA for a CAR T-cell therapy in autoimmune disease, paving the way for a potential new standard of care with a single dose, designed to reset the immune system and free patients from lifelong disease and chronic immunotherapies,” said Warner Biddle, Chief Executive Officer of Kyverna. “We believe miv-cel’s clinical profile, differentiated construct design and established manufacturing process can support a strong launch in SPS, if approved. We continue to advance our commercial readiness activities by hiring key commercial leaders with deep expertise in CAR T, neurology, and rare disease launches, initiating the critical field infrastructure, and working with treatment centers to prepare for potential patient access. Our progress to date is a testament to the dedication of our employees, investigators, patients, and partners. SPS is our lead indication, but we believe it is only the beginning of a much broader opportunity to transform the treatment paradigm for neurologic autoimmune diseases.”

Execution of Miv-cel BLA Submission for SPS Seeking Priority Review

• Kyverna has completed the submission of its rolling Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), seeking priority review of miv-cel (mivocabtagene autoleucel, KYV-101) in stiff person syndrome (SPS) under its Regenerative Medicine Advanced Therapy (RMAT) designation. The BLA submission is based on a comprehensive positive data package from the KYSA-8 registrational trial in patients with SPS.
• In anticipation of a potential FDA approval and commercial launch in 2027, Kyverna is rapidly progressing launch readiness activities through targeted site activation engagements with CAR-T experts, neurologists and payers, and building an integrated patient support and reimbursement network to streamline the treatment journey. With experienced leaders in place, recruiting efforts continue for a focused group of field-based sales and medical specialists.
• One-year SPS data reported at MS Toronto in October 2026 demonstrated miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints, with nearly all patients remaining off chronic immunotherapies with a single dose. In addition, miv-cel continues to demonstrate a consistent and well-tolerated safety profile, with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), and no cases of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). The primary analysis from KYSA-8 were recently published in the Journal of American Medical Association (JAMA) Neurology, and additional one-year biomarker data from KYSA-8 will be presented at ASH 2026.

Progress in Miv-cel Neuroimmunology Franchise

• Enrollment On Track in KYSA-6 Registrational Trial for Generalized Myasthenia Gravis (gMG):
  • Phase 2 longer-term follow up data presented in September 2026 and at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting highlight that miv-cel provided a robust and durable effect for up to 1.5 years, with the majority of patients maintaining minimal symptom expression (MSE) and staying free of chronic immunotherapies after a single dose. In addition, miv-cel demonstrated a consistent and well-tolerated safety profile with no high-grade CRS, no ICANS, and no reported cases of IEC-HS.
  • The robust longer-term follow up data continue to de-risk the Phase 3 gMG trial, with enrollment expected to be completed in mid-2027.

• Progressive Multiple Sclerosis (PMS):
  • Updated Phase 1 data from an Investigator-initiated trial (IIT) conducted by Stanford University, which were presented at MS Toronto further supported that miv-cel improved disability scores while achieving robust CAR T penetration in the central nervous system (CNS) without the need for chronic immunotherapies. Durable results were achieved beyond two years in the first patient treated, underscoring the durability of treatment effect achieved with a single dose of miv-cel. Miv-cel continues to be well-tolerated with no high-grade CRS and no reported cases of ICANS or IEC-HS.
  • RMAT designation was granted by the FDA for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS). Kyverna expects to share its development strategy in PMS by early 2027.

• KYV-102 Program Update:
  • Kyverna has elected to deprioritize its KYV-102 program as the Company continues to focus on accelerating its late-stage neurologic indications with miv-cel. The Company will continue to advance lifecycle management activities for miv-cel to broaden access for patients and lower costs.

Financial Results for the Third Quarter Ended September 30, 2026

• Kyverna reported $170.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026, which, in addition to amounts available for draw from the Oxford Finance amended loan facility, is expected to provide operating runway into 2028.
• Research and Development (R&D) expenses were $27.0 million for the third quarter ended September 30, 2026.
• General and Administrative (G&A) expenses were $15.9 million for the third quarter ended September 30, 2026.
• For the third quarter ended September 30, 2026, the Company reported a net loss of $41.9 million, or a net loss per common share of $0.68.

About Miv-cel (mivocabtagene autoleucel, KYV-101)
Miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation. It is uniquely designed for potency and tolerability with the potential to achieve deep B-cell depletion, reset the immune system, and deliver durable drug-free, disease-free remission in autoimmune diseases with a single dose. Miv-cel is under investigation for B-cell driven autoimmune diseases and is produced using a well-established, validated manufacturing process. To date, more than 100 patients have been treated with miv-cel across a range of autoimmune diseases, and the clinical data demonstrates a consistent and well-tolerated safety profile.

About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a late-stage clinical immunology company pioneering differentiated therapies with curative potential for neurologic autoimmune diseases. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently submitted Biologics License Application (BLA) for miv-cel in stiff person syndrome (SPS) and an ongoing registrational trial for generalized myasthenia gravis (gMG).

Miv-cel has received three FDA Regenerative Medicine Advanced Therapy (RMAT) designations, in SPS, gMG, and non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data and significant unmet need, further reinforcing the therapy’s potential across neuroimmunology. Additionally, the Company continues to advance new innovations that broaden access and choice for patients, expanding its leadership position in the field. For more information, please visit https://kyvernatx.com. 

Forward-looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: the potential for miv-cel to be the first FDA-approved treatment for SPS and potential first approved autoimmune CAR-T therapy; the potential for miv-cel to be a new standard of care with a single dose that may reset the immune system to free patients from lifelong disease and chronic immunotherapies; Kyverna’s belief that miv-cel’s clinical profile, differentiated construct design and established manufacturing process can support a strong launch in SPS; the potential that miv-cel may be approved and potential timing for commercial launch; Kyverna’s opportunity to transform the treatment paradigm for neurologic autoimmune diseases; the KYSA-6 Phase 3 trial for gMG and expected timing for completion of enrollment in such trial; Kyverna’s readiness for commercial launch of miv-cel in SPS; Kyverna’s plans to advance lifecycle management activities for miv-cel to broaden patient access and lower costs; Kyverna’s operating runway; Kyverna’s potential first-in-class neuroimmunology CAR T franchise; the potential for miv-cel to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases; miv-cel’s potential to deliver durable, drug-free, disease-free remission in autoimmune diseases with a single dose; any potential benefits of RMAT designation for miv-cel; and Kyverna’s expected upcoming pipeline milestones, including for SPS, gMG, PMS and additional pipeline opportunities. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions; the ability to enroll patients in clinical trials on anticipated timelines; the possibility that results from prior clinical trials, named-patient access activities and preclinical studies may not necessarily be predictive of future results; the possibility that the FDA may not accept the BLA for filing or grant priority review, may require additional data, trials or studies, or may not approve miv-cel on the anticipated timeline or at all; Kyverna’s ability to successfully commercialize miv-cel, if approved; intellectual property rights; and other factors discussed in the “Risk Factors” section of Kyverna’s previously filed Annual Report on Form 10-K for the year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 to be filed with the U.S. Securities and Exchange Commission on or about the date hereof. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna’s management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information, please contact:
Investors: InvestorRelations@kyvernatx.com
Media: Media@kyvernatx.com

Kyverna Therapeutics, Inc. Condensed Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) (Unaudited)
	Three Months Ended September 30,								Nine Months Ended September 30,
	2026				2025				2026				2025
Operating expenses
Research and development	$	27,023			$	30,457			$	81,884			$	103,706
General and administrative		15,876				8,270				41,938				26,839
Total operating expenses		42,899				38,727				123,822				130,545
Loss from operations		(42,899	)			(38,727	)			(123,822	)			(130,545	)
Interest income		1,680				2,000				5,936				7,189
Interest expense		(728	)			(7	)			(2,069	)			(45	)
Other income (expense), net		6				(53	)			(33	)			(102	)
Total other income, net		958				1,940				3,834				7,042
Net loss		(41,941	)			(36,787	)			(119,988	)			(123,503	)
Other comprehensive (loss) income
Unrealized (loss) gain on available-for-sale marketable securities, net		(9	)			49				(248	)			(76	)
Total other comprehensive (loss) income		(9	)			49				(248	)			(76	)
Net loss and other comprehensive loss	$	(41,950	)		$	(36,738	)		$	(120,236	)		$	(123,579	)
Net loss per share attributable to common stockholders, basic and diluted	$	(0.68	)		$	(0.85	)		$	(1.96	)		$	(2.85	)
Weighted-average shares of common stock outstanding, basic and diluted		61,960,238				43,415,367				61,102,693				43,284,111

Kyverna Therapeutics, Inc. Condensed Balance Sheets (in thousands) (Unaudited)
		September 30,				December 31,
		2026				2025
Assets
Current assets
Cash and cash equivalents and available-for-sale marketable securities		$	170,572			$	279,253
Prepaid expenses and other current assets			5,686				3,700
Total current assets			176,258				282,953
Restricted cash			551				551
Operating lease right-of-use assets			7,492				3,568
Other non-current assets			5,136				6,754
Total assets		$	189,437			$	293,826
Liabilities and stockholders’ equity
Current liabilities		$	25,136			$	36,487
Loan payable, net			24,958				24,743
Other non-current liabilities			6,189				320
Stockholders’ equity			133,154				232,276
Total liabilities and stockholders’ equity		$	189,437			$	293,826

Toronto’s holiday windows have always been made for looking. This one is made for booking. Bringing in the thrill of discovery beyond the glass. The free, immersive dining experience in Yorkville invites guests to step inside a holiday window and discover the unexpected flavours and plot twists of the 2026 PC® Holiday Insiders Report™.

BRAMPTON, Ontario, Nov. 12, 2026 (GLOBE NEWSWIRE) — President’s Choice^® is bringing the magic of Toronto’s holiday windows beyond the glass with PC^® Bookable Window, a free, bookable holiday dining experience inspired by the 2026 PC^® Holiday Insiders Report™. Located at 131 Bloor St. W. in Toronto’s Yorkville neighbourhood, the experience will run on Thursdays and Sundays from November 10^th to December 19^th , giving guests the opportunity to step inside an immersive holiday window and discover products from this year’s report.

For generations, Toronto’s holiday window displays have been part of the ritual of the season, transforming a walk downtown into an occasion of its own. PC^® Bookable Window puts a delicious spin on that tradition, inviting guests to step beyond the glass and experience the thrill of discovery firsthand. Through an immersive dining experience inspired by the 2026 PC^® Holiday Insiders Report™, guests will discover unexpected flavours, creative twists and new products designed to shake up the holiday season.

“Holiday windows have a special place in Toronto’s history because they turn something as simple as walking down the street into a shared seasonal tradition,” says Lindsay Cook, VP, Control Brand, Loyalty and Joe Fresh Marketing, Loblaw Companies Ltd. “With PC^® Bookable Window, we created a one-of-a-kind experience to reimagine that feeling through something President’s Choice has always believed in: the power of great food to bring people together. By inviting people beyond the glass and around the table, we’re giving Canadians a new way to discover the creativity, flavour and unexpected twists behind this year’s PC^® Holiday Insiders Report™.”

A Holiday Tradition, Reimagined

At the heart of the experience is what President’s Choice^® does best: bringing unexpected creativity and innovation to great food. Featuring more than 100 new launches and 20 Must-Try products, the 2026 PC^® Holiday Insiders Report™ is full of delicious discoveries designed to inspire new traditions, elevate holiday entertaining and bring something unexpected to the table.

Highlights will include the PC^® Buttermilk-Brined Young Turkey, a first-for-Canada take that puts a new spin on the classic holiday centrepiece. PC^® Beef Wellie Bites, a main-course moment reimagined into the perfect party bite, and PC^® Our Ultimate Butter Tart Pie, a holiday dessert mashup featuring Canadian cranberries.

How to Experience PC^® Bookable Window

PC^® Bookable Window will run at 131 Bloor St. W. from November 19 to December 19, with 19 bookable dining experiences offered on Thursday, Friday, Saturday evenings and Sunday afternoons.

Each free dining experience will accommodate up to 12 guests, with reservations available for parties of varying sizes through OpenTable via a custom President’s Choice^® landing page. Reservations will be released in two waves:

• November 12th @ 8:00am ET
• November 26th @ 8:00am ET

The discovery doesn’t stop at the dinner table. Throughout the holiday season, PC^® Bookable Window will also come alive for passersby on Bloor Street. With a simple wave, visitors can activate a moving display of colourful lights, explore featured products from the PC^® Holiday Insiders Report™ and scan to shop their discoveries through PC Express™. Guests can also access the booking page directly from the window.

PC^® Bookable Window marks the fourth free immersive, bookable PC^® experience in the past two years, following PC^® Bookable Backyards, PC^® Kitchen Drop and PC^® House. It continues the brand’s commitment to bringing the latest in culinary innovation to life through unforgettable experiences, creating new ways for Canadians to come together, connect and discover what’s next from PC^®.

See It. Book It. Taste It.

Experience PC^® Bookable Window: Visit pcoptimum.ca/pcbookablewindow.
Discover the 2026 PC^® Holiday Insiders Report™: Explore the full report through the PC Optimum™ App and participating banner sites.
Taste the collection: Featured PC^® Holiday Insiders Report™ products are available at participating Loblaw banner stores.

Media inquiries: pr@loblaw.ca

About Loblaw Companies Limited
Loblaw is Canada’s food and pharmacy leader, and the nation’s largest retailer. Loblaw provides Canadians with grocery, pharmacy, and healthcare services, other health and beauty products, apparel, general merchandise, financial services and wireless mobile products and services. With more than 2,800 locations, Loblaw, its franchisees and Associate-owners employ more than 220,000 full- and part-time employees, making it one of Canada’s largest private sector employers.

Loblaw’s purpose – Live Life Well^® – puts first the needs and well-being of Canadians who make one billion transactions annually in the company’s stores. Loblaw is positioned to meet and exceed those needs in many ways: convenient locations; more than 1,100 grocery stores that span the value spectrum from discount to specialty; full-service pharmacies at nearly 1,400 Shoppers Drug Mart^® and Pharmaprix^® locations and in close to 500 grocery stores; PC Financial^® services; Joe Fresh^® fashion and family apparel; and four of Canada’s top-consumer brands in Life Brand^®, Farmer’s Market™, no name^® and President’s Choice^®. For more information, visit Loblaw’s website at www.loblaw.ca and Loblaw’s issuer profile at www.sedarplus.ca

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a43db449-a163-4ec9-b068-768deb3ac4e3